Biogen CEO Michel Vounatsos On Approval Of Alzheimer’s Drug
First on CNBC: CNBC Transcript: Biogen Inc (NASDAQ:BIIB) CEO Michel Vounatsos Speaks with CNBC’s “Power Lunch” today, discussing FDA’s approval of its Alzheimer’s drug. Q1 2021 hedge fund letters, conferences and more WHEN: Today, Monday, June 7 WHERE: CNBC’s “Power Lunch” Biogen CEO On FDA Approval For Its Alzheimer’s DrugAll references must be sourced to CNBC. MEG TIRRELL: Kelly, thanks so much. Michel Vounatsos joins us now, the news of the week, the year, this is huge. Michel, the first Alzheimer’s drug approved in 18 years. The first ever to potentially slow the course of the disease but ...